Search

Your search keyword '"Dees, E. Claire"' showing total 316 results
Start Over Author "Dees, E. Claire"
316 results on '"Dees, E. Claire"'

2. Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Author

Tomlins, Scott A., Khazanov, Nickolay A., Bulen, Benjamin J., Hovelson, Daniel H., Shreve, Melissa J., Lamb, Laura E., Matrana, Marc R., Burkard, Mark E., Yang, Eddy Shih-Hsin, Edenfield, William Jeffery, Dees, E. Claire, Onitilo, Adedayo A., Thompson, Michael, Buchschacher, Jr, Gary L., Miller, Alan M., Menter, Alexander, Parsons, Benjamin, Wassenaar, Timothy, Hwang, Leon C., Suga, J. Marie, Siegel, Robert, Irvin, Jr, William, Nair, Suresh, Slim, Jennifer N., Misleh, Jamal, Khatri, Jamil, Masters, Gregory, Thomas, Sachdev, Safa, Malek, Anderson, Daniel M., Kwiatkowski, Kat, Mitchell, Khalis, Hu-Seliger, Tina, Drewery, Stephanie, Fischer, Andrew, Plouffe, Komal, Czuprenski, Eric, Hipp, Jennifer, Reeder, Travis, Vakil, Hana, Johnson, D. Bryan, and Rhodes, Daniel R.

Published
2023
Full Text
View/download PDF

5. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

Author

Ademuyiwa, Foluso O., Gao, Feng, Street, Cherease R., Chen, Ina, Northfelt, Donald W., Wesolowski, Robert, Arora, Mili, Brufsky, Adam, Dees, E. Claire, Santa-Maria, Cesar A., Connolly, Roisin M., Force, Jeremy, Moreno-Aspitia, Alvaro, Herndon, John M., Carmody, Madelyn, Davies, Sherri R., Larson, Sarah, Pfaff, Kathleen L., Jones, Stephanie M., Weirather, Jason L., Giobbie-Hurder, Anita, Rodig, Scott J., Liu, Zheng, Hagemann, Ian S., Sharon, Elad, and Gillanders, William E.

Published
2022
Full Text
View/download PDF

6. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

Author

Lehmann, Brian D., primary, Abramson, Vandana G., additional, Dees, E. Claire, additional, Shah, Payal D., additional, Ballinger, Tarah J., additional, Isaacs, Claudine, additional, Santa-Maria, Cesar A., additional, An, Hanbing, additional, Gonzalez-Ericsson, Paula I., additional, Sanders, Melinda E., additional, Newsom, Kimberly C., additional, Abramson, Richard G., additional, Sheng, Quanhu, additional, Hsu, Chih-Yuan, additional, Shyr, Yu, additional, Wolff, Antonio C., additional, and Pietenpol, Jennifer A., additional

Published
2024
Full Text
View/download PDF

9. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors

Author

Vincent, Benjamin G., primary, File, Danielle M., additional, McKinnon, Karen P., additional, Moore, Dominic T., additional, Frelinger, Jeffrey A., additional, Collins, Edward J., additional, Ibrahim, Joseph G., additional, Bixby, Lisa, additional, Reisdorf, Shannon, additional, Laurie, Sonia J., additional, Park, Yara A., additional, Anders, Carey K., additional, Collichio, Frances A., additional, Muss, Hyman B., additional, Carey, Lisa A., additional, van Deventer, Hendrik W., additional, Dees, E. Claire, additional, and Serody, Jonathan S., additional

Published
2023
Full Text
View/download PDF

10. Abstract CT241: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors

Author

Abdou, Yara, primary, Dees, E. Claire, additional, Mortimer, Joanne, additional, Ueno, Naoto, additional, Johnson, Melissa, additional, Maziarz, Richard, additional, Specht, Jennifer, additional, Yuan, Yuan, additional, Puhlman, Paula, additional, Angelos, Mathew, additional, Gill, Saar, additional, Ronczka, Amy, additional, Condamine, Thomas, additional, Cushing, Daniel J., additional, Klichinsky, Michael, additional, Barton, Debora, additional, Swaby, Ramona F., additional, and Binder, Kim Reiss, additional

Published
2023
Full Text
View/download PDF

11. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study

Author

Yardley, Denise A., Reeves, James, Dees, E. Claire, Osborne, Cynthia, Paul, Devchand, Ademuyiwa, Foluso, Soliman, Hatem, Guthrie, Troy, Andersen, Jay, Krekow, Lea, Choksi, Janak, Daniel, Brooke, Danso, Michael, Favret, Anne, Oommen, Sanjay, Brufsky, Adam, Bromund, Jane L., Lin, Yong, Ibrahim, Ayman B., and Richards, Paul D.

Published
2016
Full Text
View/download PDF

12. Supplementary Table 1 and 2 from First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Author

Munster, Pamela, primary, Aggarwal, Rahul, primary, Hong, David, primary, Schellens, Jan H.M., primary, van der Noll, Ruud, primary, Specht, Jennifer, primary, Witteveen, Petronella O., primary, Werner, Theresa L., primary, Dees, E. Claire, primary, Bergsland, Emily, primary, Agarwal, Neeraj, primary, Kleha, Joseph F., primary, Durante, Michael, primary, Adams, Laurel, primary, Smith, Deborah A., primary, Lampkin, Thomas A., primary, Morris, Shannon R., primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 1 from Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Author

Dees, E. Claire, primary, Cohen, Roger B., primary, von Mehren, Margaret, primary, Stinchcombe, Thomas E., primary, Liu, Hua, primary, Venkatakrishnan, Karthik, primary, Manfredi, Mark, primary, Fingert, Howard, primary, Burris, Howard A., primary, and Infante, Jeffrey R., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Methods from Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Author

Dees, E. Claire, primary, Cohen, Roger B., primary, von Mehren, Margaret, primary, Stinchcombe, Thomas E., primary, Liu, Hua, primary, Venkatakrishnan, Karthik, primary, Manfredi, Mark, primary, Fingert, Howard, primary, Burris, Howard A., primary, and Infante, Jeffrey R., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figures 1 - 3 from Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Author

Dees, E. Claire, primary, Cohen, Roger B., primary, von Mehren, Margaret, primary, Stinchcombe, Thomas E., primary, Liu, Hua, primary, Venkatakrishnan, Karthik, primary, Manfredi, Mark, primary, Fingert, Howard, primary, Burris, Howard A., primary, and Infante, Jeffrey R., primary

Published
2023
Full Text
View/download PDF

16. Data from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Tables 1-5 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legends 1-2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

21. Abstract PD13-05: PD13-05 Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status

Author

Wesolowski, Robert, primary, Rugo, Hope, additional, Stringer-Reasor, Erica, additional, Han, Hyo S., additional, Specht, Jennifer M., additional, Dees, E. Claire, additional, Kabos, Peter, additional, Vaishampayan, Ulka, additional, Wander, Seth A., additional, Lu, Janice, additional, Gogineni, Keerthi, additional, Spira, Alexander I., additional, Schott, Anne F., additional, Abu-Khalaf, Maysa, additional, Nayak, Pratima, additional, Sullivan, Brian F., additional, Gorbatchevsky, Igor, additional, and Layman, AND Rachel M., additional

Published
2023
Full Text
View/download PDF

23. A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects

Author

Nakamura, Zev M., primary, Deal, Allison M., additional, Park, Eliza M., additional, Stanton, Kate E., additional, Lopez, Yesy E., additional, Quillen, Laura J., additional, O’Hare Kelly, Erin, additional, Heiling, Hillary M., additional, Nyrop, Kirsten A., additional, Ray, Emily M., additional, Dees, E. Claire, additional, Reeder‐Hayes, Katherine E., additional, Jolly, Trevor A., additional, Carey, Lisa A., additional, Abdou, Yara, additional, Olajide, Oludamilola A., additional, Rauch, Julia K., additional, Joseph, Ranjit, additional, Copeland, Anureet, additional, McNamara, Megan A., additional, Ahles, Tim A., additional, and Muss, Hyman B., additional

Published
2023
Full Text
View/download PDF

24. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Author

Melichar, Bohuslav, Adenis, Antoine, Lockhart, A Craig, Bennouna, Jaafar, Dees, E Claire, Kayaleh, Omar, Obermannova, Radka, DeMichele, Angela, Zatloukal, Petr, Zhang, Bin, Ullmann, Claudio Dansky, and Schusterbauer, Claudia

Published
2015
Full Text
View/download PDF

26. Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages

Author

Lee, Michael S., Dees, E. Claire, and Wang, Andrew Z.

Subjects
Cancer -- Drug therapy -- Comparative analysis -- Health aspects, Hyaluronidase -- Comparative analysis -- Health aspects, Dendrimers -- Comparative analysis -- Health aspects, Vincristine -- Comparative analysis -- Health aspects, Permeability -- Comparative analysis -- Health aspects, Drug approval -- Comparative analysis -- Health aspects, Chemotherapy -- Comparative analysis -- Health aspects, Toxicity, Nanoparticles, Tumors, Respiratory system agents, Antineoplastic agents, Therapeutics, Clinical trials, Drugs, Health
Abstract

Cytotoxic chemotherapies have a narrow therapeutic window, with high peaks and troughs of plasma concentration. Novel nanoparticle formulations of cytotoxic chemotherapy drugs can enhance pharmacokinetic characteristics and facilitate passive targeting of drugs to tumors via the enhanced permeability and retention effect, thus mitigating toxicity. Nanoparticle vehicles currently in clinical use or undergoing clinical investigation for anticancer therapies include liposomes, polymeric micelles, protein-drug nanoparticles, and dendrimers. Multiple nanoparticle formulations of existing cytotoxic chemotherapies are approved for use in several indications, with clinical data indeed showing optimization of pharmacokinetics and different toxicity profiles compared with their parent drugs. There are also many new nanoparticle drug formulations in development and undergoing early- and late-phase clinical trials, including several that utilize active targeting or triggered release based on environmental stimuli. Here, we review the rationale for nanoparticle formulations of existing or previously investigated cytotoxic drugs, describe currently approved nanoparticle formulations of drugs, and discuss some of the most promising clinical trials currently underway., Introduction and Rationale for Nanoparticle Reformulations While cytotoxic chemotherapies form a cornerstone of anticancer treatment, they universally have narrow therapeutic windows. Within the last 2 decades, novel formulations of chemotherapeutics [...]

Published
2017

27. Abstract CT524: A phase 1, first in human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophages (CAR-M) in HER2-overexpressing solid tumors (ST)

Author

Reiss, Kim A., primary, Yuan, Yuan, additional, Ueno, Naoto T., additional, Abdou, Yara, additional, Barton, Debora, additional, Swaby, Ramona F., additional, Ronczka, Amy, additional, Cushing, Daniel J., additional, Abramson, Sascha, additional, Condamine, Thomas, additional, Klichinsky, Michael, additional, and Dees, E. Claire, additional

Published
2022
Full Text
View/download PDF

28. Body Mass Index and patient-reported measures of function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer

Author

Nyrop, Kirsten A., primary, Monaco, Jane, additional, Vohra, Sanah, additional, Deal, Allison, additional, Wood, William A, additional, Shachar, Shlomit S, additional, Dees, E Claire, additional, Kimmick, Gretchen G, additional, Speca, JoEllen C, additional, and Muss, Hyman B, additional

Published
2022
Full Text
View/download PDF

31. Abstract PD13-02: Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer

Author

Layman, Rachel, primary, Wesolowski, Robert, additional, Han, Hyo, additional, Specht, Jennifer M, additional, Stringer-Reasor, Erica M, additional, Dees, E. Claire, additional, Kabos, Peter, additional, Mayer, Ingrid A, additional, Vaishampayan, Ulka, additional, Lu, Janice, additional, Gogineni, Keerthi, additional, Bardia, Aditya, additional, Schott, Anne F, additional, Abu-Khalaf, Maysa, additional, Howkins, Doug, additional, Sullivan, Brian, additional, Gorbatchevsky, Igor, additional, and Rugo, Hope, additional

Published
2022
Full Text
View/download PDF

32. Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study

Author

Hamilton, Erika P, primary, Wang, Judy S, additional, Pluard, Timothy, additional, Morikawa, Aki, additional, Dees, E Claire, additional, Jones, Robert H, additional, Haley, Barbara, additional, Armstrong, Anne, additional, Cohen, Adam L, additional, Munster, Pamela, additional, Wright, Gail S, additional, Kayali, Fadi, additional, Cantagallo, Lisa, additional, Korpal, Manav, additional, Long, Jenny, additional, Xiao, Jianjun, additional, Destenaves, Benoit, additional, Gao, Lei, additional, Sahmoud, Tarek, additional, Gualberto, Antonio, additional, and Juric, Dejan, additional

Published
2022
Full Text
View/download PDF

33. A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

Author

Mitin, Natalia, primary, Nyrop, Kirsten A., additional, Strum, Susan L., additional, Knecht, Anne, additional, Carey, Lisa A, additional, Reeder-Hayes, Katherine E., additional, Dees, E. Claire, additional, Jolly, Trevor A., additional, Kimmick, Gretchen G., additional, Karuturi, Meghan S., additional, Reinbolt, Raquel E., additional, Speca, JoEllen C., additional, O’Hare, Erin A., additional, and Muss, Hyman B., additional

Published
2022
Full Text
View/download PDF

34. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Author

Tolaney, Sara M., primary, Beeram, Muralidhar, additional, Beck, J. Thaddeus, additional, Conlin, Alison, additional, Dees, E. Claire, additional, Puhalla, Shannon L., additional, Rexer, Brent N., additional, Burris, Howard A., additional, Jhaveri, Komal, additional, Helsten, Teresa, additional, Becerra, Carlos, additional, Kalinsky, Kevin, additional, Moore, Kathleen N., additional, Manuel, Allison M., additional, Lithio, Andrew, additional, Price, Gregory L., additional, Chapman, Sonya C., additional, Litchfield, Lacey M., additional, and Goetz, Matthew P., additional

Published
2022
Full Text
View/download PDF

35. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Author

Anders, Carey K, primary, Woodcock, Mark G, additional, Van Swearingen, Amanda E D, additional, Moore, Dominic T, additional, Sambade, Maria J, additional, Laurie, Sonia, additional, Robeson, Alexander, additional, Kolupaev, Oleg, additional, Cuaboy, Luz A, additional, Garrett, Amy L, additional, McKinnon, Karen, additional, Cowens, Kristen, additional, Bortone, Dante, additional, Calhoun, Benjamin C, additional, Wilkinson, Alec D, additional, Carey, Lisa, additional, Jolly, Trevor, additional, Muss, Hyman, additional, Reeder-Hayes, Katherine, additional, Kaltman, Rebecca, additional, Jankowitz, Rachel, additional, Gudena, Vinay, additional, Olajide, Oludamilola, additional, Perou, Charles, additional, Dees, E Claire, additional, Vincent, Benjamin G, additional, and Serody, Jonathan S, additional

Published
2022
Full Text
View/download PDF

48. Abstract PS12-04: Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection

Author

Aftimos, Philippe, primary, Neven, Patrick, additional, Pegram, Mark, additional, van Oordt, Catharina Willemien Menke-van der Houven, additional, Dees, E. Claire, additional, Schröder, Carolien, additional, Jager, Agnes, additional, Bulat, Iurie, additional, Chap, Linnea, additional, Maglakelidze, Marina, additional, Hamilton, Erika, additional, Cristofanilli, Massimo, additional, Ulahannan, Susanna, additional, Boers, Jorianne, additional, Iqbal, Ramsha, additional, Crijanovschi, Adrian, additional, Wolfgang, Curt D, additional, Tao, Wenli, additional, Sipes, Christina, additional, Malik, Rajesh, additional, and Jain, Sarika, additional

Published
2021
Full Text
View/download PDF

49. Abstract PD8-07: Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

Author

Aftimos, Philippe, primary, Maglakelidze, Marina, additional, Glaudemans, Andor WJM, additional, Hamilton, Erika, additional, Chap, Linnea, additional, de Vries, Elisabeth, additional, Menke-van der Houven van Oordt, Catharina Willemien, additional, Jager, Agnes, additional, Dees, E. Claire, additional, Cristofanilli, Massimo, additional, Pegram, Mark, additional, Ulahannan, Susanna, additional, Neven, Patrick, additional, Bulat, Iurie, additional, Rai, Ruhi, additional, Tao, Wenli, additional, Jain, Sarika, additional, Beelen, Andrew P, additional, and Sorrentino, Jessica A, additional

Published
2021
Full Text
View/download PDF

50. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Author

Harvey, R. Donald, primary, Mileham, Kathryn F., additional, Bhatnagar, Vishal, additional, Brewer, Jamie R., additional, Rahman, Atiqur, additional, Moravek, Cassadie, additional, Kennedy, Andrew S., additional, Ness, Elizabeth A., additional, Dees, E. Claire, additional, Ivy, S. Percy, additional, Ebbinghaus, Scot W., additional, Schenkel, Caroline, additional, and Uldrick, Thomas S., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results